Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy
Explore this paper's citation graph
Summary
A previously unrecognized pathway for the activation of tumor antigen–specific T-cell immunity that involves secretion of the high-mobility-group box 1 (HMGB1) alarmin protein by dying tumor cells and the action of HMGB1 on Toll-like receptor 4 (TLR4) expressed by dendritic cells (DCs) is described.
- Type
- article
- Published
- 2007-09-01
- Cited by
- 3,031
- References
- 49
- OpenAlex
- https://openalex.org/W2093424661
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:13691461
Keywords
Immunogenic cell death, Immunoadjuvant, Radiation therapy, Immune system, Cancer research
References
- TLR4 mutations are associated with endotoxin hyporesponsiveness in humans
- Toll-like receptors and innate immunity
- Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs
- Extracellular ATP Induces a Distorted Maturation of Dendritic Cells and Inhibits Their Capacity to Initiate Th1 Responses1
- High Mobility Group Box Protein 1: An Endogenous Signal for Dendritic Cell Maturation and Th1 Polarization
- Inhibitory Effect of Toll-Like Receptor 4 on Fusion between Phagosomes and Endosomes/Lysosomes in Macrophages1
- On regulation of phagosome maturation and antigen presentation
- Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses
- Innate Immunity: The Virtues of a Nonclonal System of Recognition
- Enhanced Dendritic Cell Antigen Capture via Toll-Like Receptor-Induced Actin Remodeling
- Single step high-throughput determination of Toll-like receptor 4 polymorphisms.
- Toll-like receptors in systemic autoimmune disease
- The Unc93b1 mutation 3d disrupts exogenous antigen presentation and signaling via Toll-like receptors 3, 7 and 9
- Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody.
- Release of chromatin protein HMGB1 by necrotic cells triggers inflammation
- Calreticulin exposure dictates the immunogenicity of cancer cell death
- Lymphocyte responses: NFAT5: helping out in stressful times
- Efficient T cell activation via a Toll-Interleukin 1 Receptor-independent pathway.
- Differential Priming to Programmed Cell Death of Superantigen-Reactive Lymphocytes of HIV Patients
- Regulation of lung injury and repair by Toll-like receptors and hyaluronan
Cited by
- Leveraging the immune system during chemotherapy: moving calreticulin to the cell surface converts apoptotic death from "silent" to immunogenic.
- HMGB1: Endogenous Danger Signaling
- Toll-like receptors: lessons to learn from normal and malignant human B cells.
- Glutaredoxin regulation of pro -inflammatory responses in a model of diabetic retinopathy
- T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers
- Milk fat globule epidermal growth factor–8 blockade triggers tumor destruction through coordinated cell-autonomous and immune-mediated mechanisms
- HPV-induced oropharyngeal cancer, immune response and response to therapy.
- Development of a Cancer Vaccine Targeting Tumor Blood Vessels
- A novel inflammatory regulator TIPE2 inhibits TLR4-mediated development of colon cancer via caspase-8
- Intestinal Bacteria and the Regulation of Immune Cell Homeostasis
- Toll-like receptors: expression and involvement in multiple myeloma.
- Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer
- Intracellular and extracellular cytokine-like functions of prothymosin α: implications for the development of immunotherapies.
- Extracellular NM23 Protein as a Therapeutic Target for Hematologic Malignancies
- CD24 Ala57Val polymorphism predicts pathologic complete response to sequential anthracycline- and taxane-based neoadjuvant chemotherapy for primary breast cancer
- Toll-Like Receptor 4 Activation in Cancer Progression and Therapy
- Innate immune sensing of cancer: clues from an identified role for type I IFNs
- CpG plus radiotherapy: a review of preclinical works leading to clinical trial
- Trial Watch
- Cetuximab-mediated tumor regression depends on innate and adaptive immune responses.
Related papers
- The HMGB1-TLR4 axis contributes to myocardial ischemia/reperfusion injury via regulation of cardiomyocyte apoptosis.
- Toll-like receptor 4 (TLR4) and interferon-gamma (IFN-r) are required for HMGB1-induced TNF release from macrophages.
- The time related concentration of serum HMGB1 and TLR4 in CLP rat model
- Toll-like Receptor 4 (TLR4) Antagonist Eritoran Tetrasodium Attenuates Liver Ischemia and Reperfusion Injury through Inhibition of High-Mobility Group Box Protein B1 (HMGB1) Signaling
- Potential anti-inflammatory effect of anti-HMGB1 in animal models of ICH by downregulating the TLR4 signaling pathway and regulating the inflammatory cytokines along with increasing HO1 and NRF2.
- Ketamine effect on HMGB1 and TLR4 expression in rats with acute lung injury.
- High-Mobility Group Box-1 Mediates Toll-Like Receptor 4–Dependent Angiogenesis
- Regulatory Effect of the HMGB1-TLR4 Signaling Pathway in Pulmonary Ischemia/Reperfusion.
- Upregulation of toll-like receptor 4 (TLR4)/MD-2 complex in LPS hypersensitive livers in mice